More good news?

The good news keeps arriving regarding the CoViD-19 vaccine together with a continued increase in the infections worldwide. We can now be reasonably certain that the pandemics will be brought to heel in second half of 2021. The stock markets react as if the virus has already gone, while...

Origo Insights

A vaccine against the depression

A vaccine against the depression

The joint statement from Pfizer and BioNtech of successful phase three trials of vaccine against CoVid-1 has the potential to be the next game changing event in the SARS 2 CoViD-19 saga. We are nowhere near having the...

Benchmarks? Do we need them?

Benchmarks? Do we need them?

New benchmark recommendations from ESMA aim to correct the way funds are using benchmarks. Since the introduction of the Benchmark Directive in 2018, many funds have effectively removed relevant benchmarks and replaced them...

A correction or just volatility?

A correction or just volatility?

The Covid pandemic (a once in a century event, one hopes) again accelerates briskly across Europe. The US Federal Reserve Bank has revised its policy objective (a once in three decades event). Debt levels are soaring (to...

Risk allocation is neutral

Risk allocation is neutral

Active Risk Allocation (ARA) update: The recommended risk allocation has stabilised around neutral after a short period of advising slightly below average risk exposure. Seen from a top-down view allocation is merely...

Explore Origo

Services

We offer assistance at several points along the value chain of asset and wealth management

Clients

We offer assistance at several points along the value chain of asset and wealth management

About Us

We assist wealth owners and  professional asset managers in shaping their readiness

Origo